Medtronic PLC $MDT Stock: HighTower Advisors LLC Trims Holdings

HighTower Advisors LLC lowered its stake in shares of Medtronic PLC (NYSE:MDT – Free Report) by 5.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 372,348 shares of the medical technology company’s stock after selling 20,980 shares during the quarter. HighTower Advisors LLC’s holdings in Medtronic were worth $32,130,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in shares of Medtronic by 0.7% during the second quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock valued at $8,919,846,000 after purchasing an additional 838,220 shares during the last quarter. State Street Corp increased its holdings in shares of Medtronic by 2.7% in the second quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock valued at $5,005,320,000 after purchasing an additional 1,658,301 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Medtronic by 5.4% in the first quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock valued at $2,254,200,000 after purchasing an additional 1,343,220 shares in the last quarter. First Eagle Investment Management LLC increased its holdings in shares of Medtronic by 37.2% in the second quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock valued at $1,078,321,000 after purchasing an additional 3,739,288 shares in the last quarter. Finally, Amundi raised its position in Medtronic by 36.3% in the 1st quarter. Amundi now owns 6,070,236 shares of the medical technology company’s stock worth $525,986,000 after purchasing an additional 1,616,739 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Down 0.7%

Shares of NYSE MDT opened at $99.88 on Friday. The firm has a market capitalization of $127.75 billion, a PE ratio of 24.60, a price-to-earnings-growth ratio of 2.41 and a beta of 0.56. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The firm’s 50-day moving average is $94.62 and its 200-day moving average is $88.45.

Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. The company had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. Medtronic’s revenue was up 13.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities analysts expect that Medtronic PLC will post 5.98 EPS for the current year.

Insiders Place Their Bets

In other Medtronic news, EVP Michael Marinaro sold 10,420 shares of the company’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the completion of the sale, the executive vice president owned 105,916 shares in the company, valued at approximately $10,167,936. The trade was a 8.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the transaction, the executive vice president directly owned 42,186 shares in the company, valued at approximately $3,950,718.90. This trade represents a 3.40% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 61,903 shares of company stock valued at $5,889,203. Company insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

MDT has been the topic of several research reports. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $118.00 price objective on shares of Medtronic in a report on Wednesday, September 2nd. Wall Street Zen lowered Medtronic from a “buy” rating to a “hold” rating in a research report on Monday, November 16th. Robert W. Baird lifted their target price on Medtronic from $91.00 to $100.00 and gave the company a “neutral” rating in a research note on Wednesday, September 2nd. Wells Fargo & Company lifted their target price on Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a research note on Wednesday, September 2nd. Finally, BTIG Research boosted their target price on Medtronic from $99.00 to $109.00 and gave the stock a “buy” rating in a research report on Thursday. Eighteen investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.17.

Get Our Latest Stock Analysis on MDT

About Medtronic

(Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Featured Stories

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.